Top Markets
#1 Black Phoenix Black Phoenix +736.22%
#2 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +25.77%
#3 Wrapped STX (Velar) Wrapped STX (Velar) +17.16%
#4 Verus Coin Verus Coin +14.55%
#5 Gas Gas +10.64%
#6 Akedo Akedo +8.92%
#7 MetaDAO MetaDAO +7.62%
#8 Ontology Ontology +5.43%
#9 Ontology Gas Ontology Gas +5.36%
#10 wojak wojak +5.16%
Coin of the day
Black Phoenix Black Phoenix
Settings
Language
ENGLISH
Currency
USD
Theme
MBX Biosciences, Inc. Common Stock MBX Biosciences, Inc. Common Stock

MBX Biosciences, Inc. Common Stock

MBX
Rank in Stocks #4855
MBX Biosciences, Inc. is a biopharmaceutical company in its clinical... MBX Biosciences, Inc. is a biopharmaceutical company in its clinical development phase, dedicated to pioneering precise peptide-based therapies for endocrine and metabolic conditions. Its most advanced drug candidate, MBX 2109, is a parathyroid hormone peptide prodrug currently in Phase 2 clinical trials. This medication is being evaluated as a long-duration hormone replacement treatment for individuals suffering from chronic hypoparathyroidism. The company is also progressing with MBX 1416, a prolonged-action glucagon-like peptide-1 (GLP-1) receptor antagonist, which is undergoing Phase 1 clinical assessment. The aim of this therapy is to address post-bariatric hypoglycemia, a persistent complication often seen after weight-loss surgery. Furthermore, MBX Biosciences is developing MBX 4291, a key candidate for obesity treatment. This highly potent and long-acting prodrug functions as a co-agonist for both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. It is currently in investigational new drug (IND)-enabling studies, with the intention of treating obesity and its associated health issues. Founded in 2018, the company's operations are headquartered in Carmel, Indiana.
Share Price
$67.63
Market Cap
$3.22B
Change (1 day)
-1.45%
Change (1 year)
339.98%
Country
US
Trade MBX Biosciences, Inc. Common Stock (MBX)

Category

Healthcare
P/E ratio for MBX Biosciences, Inc. Common Stock (MBX)
P/E ratio as of 2026 TTM: 0
According to MBX Biosciences, Inc. Common Stock latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for MBX Biosciences, Inc. Common Stock from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.